These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 9069288)
1. Activation of Stat1 by mutant fibroblast growth-factor receptor in thanatophoric dysplasia type II dwarfism. Su WC; Kitagawa M; Xue N; Xie B; Garofalo S; Cho J; Deng C; Horton WA; Fu XY Nature; 1997 Mar; 386(6622):288-92. PubMed ID: 9069288 [TBL] [Abstract][Full Text] [Related]
2. The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum. Lievens PM; Liboi E J Biol Chem; 2003 May; 278(19):17344-9. PubMed ID: 12624096 [TBL] [Abstract][Full Text] [Related]
3. Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells. Nowroozi N; Raffioni S; Wang T; Apostol BL; Bradshaw RA; Thompson LM Hum Mol Genet; 2005 Jun; 14(11):1529-38. PubMed ID: 15843401 [TBL] [Abstract][Full Text] [Related]
4. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Hart KC; Robertson SC; Kanemitsu MY; Meyer AN; Tynan JA; Donoghue DJ Oncogene; 2000 Jul; 19(29):3309-20. PubMed ID: 10918587 [TBL] [Abstract][Full Text] [Related]
5. Sustained phosphorylation of mutated FGFR3 is a crucial feature of genetic dwarfism and induces apoptosis in the ATDC5 chondrogenic cell line via PLCgamma-activated STAT1. Harada D; Yamanaka Y; Ueda K; Nishimura R; Morishima T; Seino Y; Tanaka H Bone; 2007 Aug; 41(2):273-81. PubMed ID: 17561467 [TBL] [Abstract][Full Text] [Related]
6. Differential activation of cysteine-substitution mutants of fibroblast growth factor receptor 3 is determined by cysteine localization. Adar R; Monsonego-Ornan E; David P; Yayon A J Bone Miner Res; 2002 May; 17(5):860-8. PubMed ID: 12009017 [TBL] [Abstract][Full Text] [Related]
7. Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia. Naski MC; Wang Q; Xu J; Ornitz DM Nat Genet; 1996 Jun; 13(2):233-7. PubMed ID: 8640234 [TBL] [Abstract][Full Text] [Related]
8. Overexpression of FGFR3, Stat1, Stat5 and p21Cip1 correlates with phenotypic severity and defective chondrocyte differentiation in FGFR3-related chondrodysplasias. Legeai-Mallet L; Benoist-Lasselin C; Munnich A; Bonaventure J Bone; 2004 Jan; 34(1):26-36. PubMed ID: 14751560 [TBL] [Abstract][Full Text] [Related]
9. Expression of fibroblast growth factor receptor-3 (FGFR3), signal transducer and activator of transcription-1, and cyclin-dependent kinase inhibitor p21 during endochondral ossification: differential role of FGFR3 in skeletal development and fracture repair. Nakajima A; Shimizu S; Moriya H; Yamazaki M Endocrinology; 2003 Oct; 144(10):4659-68. PubMed ID: 12960068 [TBL] [Abstract][Full Text] [Related]
10. FGFR3 isoforms have distinct functions in the regulation of growth and cell morphology. Shimizu A; Takashima Y; Kurokawa-Seo M Biochem Biophys Res Commun; 2002 Jan; 290(1):113-20. PubMed ID: 11779141 [TBL] [Abstract][Full Text] [Related]
11. A Lys644Glu substitution in fibroblast growth factor receptor 3 (FGFR3) causes dwarfism in mice by activation of STATs and ink4 cell cycle inhibitors. Li C; Chen L; Iwata T; Kitagawa M; Fu XY; Deng CX Hum Mol Genet; 1999 Jan; 8(1):35-44. PubMed ID: 9887329 [TBL] [Abstract][Full Text] [Related]
12. FGF signaling activates STAT1 and p21 and inhibits the estrogen response and proliferation of MCF-7 cells. Johnson MR; Valentine C; Basilico C; Mansukhani A Oncogene; 1998 May; 16(20):2647-56. PubMed ID: 9632141 [TBL] [Abstract][Full Text] [Related]
13. A central nervous system specific mouse model for thanatophoric dysplasia type II. Lin T; Sandusky SB; Xue H; Fishbein KW; Spencer RG; Rao MS; Francomano CA Hum Mol Genet; 2003 Nov; 12(21):2863-71. PubMed ID: 12966031 [TBL] [Abstract][Full Text] [Related]
14. Endothelial receptor tyrosine kinases activate the STAT signaling pathway: mutant Tie-2 causing venous malformations signals a distinct STAT activation response. Korpelainen EI; Kärkkäinen M; Gunji Y; Vikkula M; Alitalo K Oncogene; 1999 Jan; 18(1):1-8. PubMed ID: 9926914 [TBL] [Abstract][Full Text] [Related]
15. Reduced binding of FGF1 to mutant fibroblast growth factor receptor 3. Khnykin D; Olsnes S Growth Factors; 2006 Jun; 24(2):111-9. PubMed ID: 16801131 [TBL] [Abstract][Full Text] [Related]
16. Mutations in the fibroblast growth factor receptor 3 (FGFR3) cause achondroplasia, hypochondroplasia, and thanatophoric dysplasia: Taiwanese data. Tsai FJ; Tsai CH; Chang JG; Wu JY Am J Med Genet; 1999 Sep; 86(3):300-1. PubMed ID: 10482885 [No Abstract] [Full Text] [Related]
17. Fibroblast growth factor receptor-induced phosphorylation of STAT1 at the Golgi apparatus without translocation to the nucleus. Citores L; Bai L; Sørensen V; Olsnes S J Cell Physiol; 2007 Jul; 212(1):148-56. PubMed ID: 17311277 [TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-1 rescues the mutated FGF receptor 3 (G380R) expressing ATDC5 cells from apoptosis through phosphatidylinositol 3-kinase and MAPK. Koike M; Yamanaka Y; Inoue M; Tanaka H; Nishimura R; Seino Y J Bone Miner Res; 2003 Nov; 18(11):2043-51. PubMed ID: 14606518 [TBL] [Abstract][Full Text] [Related]
19. Parathyroid hormone receptor type 1/Indian hedgehog expression is preserved in the growth plate of human fetuses affected with fibroblast growth factor receptor type 3 activating mutations. Cormier S; Delezoide AL; Benoist-Lasselin C; Legeai-Mallet L; Bonaventure J; Silve C Am J Pathol; 2002 Oct; 161(4):1325-35. PubMed ID: 12368206 [TBL] [Abstract][Full Text] [Related]
20. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. d'Avis PY; Robertson SC; Meyer AN; Bardwell WM; Webster MK; Donoghue DJ Cell Growth Differ; 1998 Jan; 9(1):71-8. PubMed ID: 9438390 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]